Literature DB >> 19320649

Should macroprolactin be measured in all hyperprolactinaemic sera?

T Joseph McKenna1.   

Abstract

Macroprolactin is a nonbioactive prolactin isoform usually composed of a monomer of prolactin and a IgG molecule which has a prolonged clearance rate similar to that of the immunoglobulins. Macroprolactinaemia, hyperprolactinaemia entirely accounted for by the presence of macroprolactin, is estimated to account for approximately 10% of all hyperprolactinaemia coming to clinical attention in the United Kingdom and the United States. Failure to recognize that macroprolactinaemia can explain hyperprolactinaemia, leads to unnecessary investigation, incorrect diagnosis and inappropriate treatment. Screening of hyperprolactinaemic sera for the presence of misleading concentrations of macroprolactin is readily performed in biochemistry laboratories although the procedures have not been automated. The most widely employed method is to treat the hyperprolactinaemic sera with polyethylene glycol which precipitates out high-molecular weight constituents including immunoglobulins. Re-assay of the sera for prolactin will then identify those sera which yield values within the relevant normal range indicative of macroprolactinaemia and not true hyperprolactinaemia. The case for the routine screening of all hyperprolactinaemic sera for macroprolactin is compelling. The consequences of failure to recognize macroprolactinaemia are significant, the problem is frequently encountered, the means of addressing it are immediately available and it is cost effective.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19320649     DOI: 10.1111/j.1365-2265.2009.03577.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

1.  Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.

Authors:  Gonca Tamer; Ayşegül Telci; Meral Mert; Ayse Kubat Uzum; Ferihan Aral; Refik Tanakol; Sema Yarman; Harika Boztepe; Nese Colak; Faruk Alagöl
Journal:  Endocrine       Date:  2011-09-30       Impact factor: 3.633

Review 2.  New insights in prolactin: pathological implications.

Authors:  Valérie Bernard; Jacques Young; Philippe Chanson; Nadine Binart
Journal:  Nat Rev Endocrinol       Date:  2015-03-17       Impact factor: 43.330

Review 3.  Hyperprolactinaemia.

Authors:  Angela X Chen; Morton G Burt
Journal:  Aust Prescr       Date:  2017-12-04

4.  A New Method of Using Polyethylene Glycol (PEG) Precipitation of Macroprolactin to Detect Genuine Hyperprolactinemia.

Authors:  Yongjian Chen; Huan Wang; Wei Yang; Weidong Jin; Wenge Yu; Wei Wang; Kailin Zhang; Guangzhong Song
Journal:  J Clin Lab Anal       Date:  2016-05-24       Impact factor: 2.352

5.  Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study.

Authors:  Sollip Kim; Young-Min Park
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

Review 6.  Global Prevalence of Macroprolactinemia among Patients with Hyperprolactinemia: A Systematic Review and Meta-Analysis.

Authors:  Noor Azlin Azraini Che Soh; Najib Majdi Yaacob; Julia Omar; Aniza Mohammed Jelani; Noorazliyana Shafii; Tuan Salwani Tuan Ismail; Wan Norlina Wan Azman; Anis Kausar Ghazali
Journal:  Int J Environ Res Public Health       Date:  2020-11-06       Impact factor: 3.390

Review 7.  Hyperprolactinemia.

Authors:  Abha Majumdar; Nisha Sharma Mangal
Journal:  J Hum Reprod Sci       Date:  2013-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.